Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.
about
Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Management of patients with hepatitis B who require immunosuppressive therapyHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedHepatitis B virus management to prevent reactivation after chemotherapy: a review.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder systemProphylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-AnalysisRisk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral ProphylaxisSystematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours.Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy.Reactivation of hepatitis B virus in patients receiving chemotherapy.Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience.Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area.Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy.Immunosuppression in Patients with Chronic Hepatitis B.Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.Safety of biologics in psoriasis.
P2860
Q26801716-A8C9C435-8AA5-4C8F-85AC-08B6A9724AC4Q26853490-019CF331-C44A-4F62-A80A-7E2E99A7D764Q28076703-AB53B6D9-EB5A-4259-8C91-D7BBA21202ABQ34397738-4386A591-D135-4D1F-AFBF-D30C7CD07381Q35037621-DA4C2AD8-9F4B-4B93-B64A-7B233D311E05Q35057889-484FFF3F-F3ED-4476-A4D5-AF6536735CAEQ35658261-599336E4-A2B0-42B2-9288-4C9C468EAB73Q35746079-3E3A4F4F-0A18-4196-B175-DEA131AAB9D7Q36001152-1B03343C-B17B-4B73-B5A3-FB54060BC441Q36220459-3CC92B98-B024-4FA6-BB02-F943C518F9CAQ36245362-1C15E672-7CF8-4B22-9460-3025B0896951Q36364001-21509A31-CEA1-44C2-AD09-BDFCB668699FQ36896193-6607B8EA-8601-4F76-9C88-1FD8B44C26EDQ36957087-494F5443-7D54-47F9-92DD-E975130025C1Q37001173-62C84DEF-7691-4855-B908-32F7349BDEB5Q38062818-262BADC9-6B78-4E6C-9408-9FE48DE48079Q38665203-27D14F07-A48D-4F47-98EB-474B77E24082Q38996149-06C4E229-6069-4070-B46C-DE0D37059989Q40122859-AD282B8C-9D01-4BDF-A5E8-08495B3ABA03Q41186450-C1470505-F619-4DFA-84B3-46D8910944F8Q42163204-2CCE47BE-D5F9-4E80-AC7F-31FA2DC9BCBEQ42764680-1EC1E16C-B168-42B7-8DAE-1B4AFC84194FQ44242208-14DED926-F1E2-4F2B-8AE6-728D1A0741DDQ45324587-1D8F7A9E-920E-4AE5-8B5D-C07FE7BE51DFQ47562286-BA112D33-B814-4F3F-9456-892B93512261Q48144965-76D97C42-D39A-496A-B0ED-CB3D92069514
P2860
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@ast
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@en
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@nl
type
label
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@ast
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@en
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@nl
prefLabel
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@ast
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@en
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@nl
P2093
P2860
P356
P1476
Prophylactic use of lamivudine ...... e-based adjuvant chemotherapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2011.4
P407
P577
2011-02-01T00:00:00Z
P5875
P6179
1022232333